



Anlon Healthcare Limited

Issue Dates - Opens: 26-08-2025 | Closes: 29-08-2025

IPO Note	<div>1. Anlon Healthcare Limited is a chemical manufacturing company engaged in manufacturing of Pharma Intermediates and active pharmaceutical ingredients.</div> <div>2. The Company produces APIs, intermediates, and health products per IP, BP, EP, JP, and USP standards.</div>
Rating	★ ★ (Average)

IPO SNAPSHOT

Issue Size	₹121.03 Crores
Issue Type	Book Building IPO
Fresh Issue	₹121.03 Crores
Offer for Sale	-
Face Value Per Share	₹10
Price Band Per Share	₹86 to ₹91
Minimum Lot Size	164 Shares
Listing On	BSE, NSE
Basis of Allotment	01/09/2025
Credit of Shares to Demat A/C	02/09/2025
Listing Date	03/09/2025
Registrar to the Issue	<u>Kfin Technologies Ltd.</u>

IPO SNAPSHOT- Anlon Healthcare Limited																																			
About the Company	<ul style="list-style-type: none"><li>Incorporated in 2013,</li><li>Anlon Healthcare Limited is a chemical manufacturing company that produces high-purity advanced pharmaceutical intermediates, which serve as raw materials or key starting materials for producing active pharmaceutical ingredients (APIs).</li><li>The Company also produces APIs used in pharmaceutical formulations for various types of Finished Dosage Forms such as tablets, capsules, ointments, and syrups, as well as ingredients for nutraceutical formulations, personal care products, and animal health products.</li><li>Their products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.</li><li>Their active pharmaceutical ingredient products are manufactured in accordance with Indian and international pharmacopeia standards such as IP, BP, EP, JP, USP.</li><li>They are one of the few manufacturers of loxoprofen sodium dihydrate in India, which is a notable API widely used in treatment of pain/inflammation association with conditions including rheumatoid arthritis, osteoarthritis, lower back pain, frozen shoulder, neck-shoulder-arm syndrome, tooth pain or after surgery, injury or tooth extraction.</li></ul>																																		
Competitive Strengths	<ul style="list-style-type: none"><li>Strong product portfolio and scalable business.</li><li>Strong Promoters and Experienced Management Team.</li><li>High entry and exit barriers due to long customer approval cycles and strict product standards.</li><li>In-house Testing, Quality Control and Quality Assurance for quality control.</li><li>Focus on Quality, Environment, Health and Safety.</li></ul>																																		
Financials (₹ in Crores)	<table><tr><th>Particulars</th><th>31-3-2023</th><th>31-3-2024</th><th>31-03-2025</th><th>Y-o-Y</th></tr><tr><td>Revenue</td><td>112.8</td><td>66.5</td><td>120.2</td><td>81%</td></tr><tr><td>EBITDA</td><td>12.4</td><td>15.4</td><td>32.2</td><td>108%</td></tr><tr><td>EBITDA Margin</td><td>11.0%</td><td>23.2%</td><td>26.8%</td><td></td></tr><tr><td>PAT</td><td>5.8</td><td>9.6</td><td>20.5</td><td>113%</td></tr><tr><td>PAT Margin</td><td>5.1%</td><td>14.4%</td><td>17.0%</td><td></td></tr></table>					Particulars	31-3-2023	31-3-2024	31-03-2025	Y-o-Y	Revenue	112.8	66.5	120.2	81%	EBITDA	12.4	15.4	32.2	108%	EBITDA Margin	11.0%	23.2%	26.8%		PAT	5.8	9.6	20.5	113%	PAT Margin	5.1%	14.4%	17.0%	
Particulars	31-3-2023	31-3-2024	31-03-2025	Y-o-Y																															
Revenue	112.8	66.5	120.2	81%																															
EBITDA	12.4	15.4	32.2	108%																															
EBITDA Margin	11.0%	23.2%	26.8%																																
PAT	5.8	9.6	20.5	113%																															
PAT Margin	5.1%	14.4%	17.0%																																
Valuation	<ul style="list-style-type: none"><li>Attributing Annualized FY25 Earnings asking P/E = 17.67</li></ul>																																		
Peers	<table><tr><th>Company Name</th><th>P/E ratio</th></tr><tr><td>Kronox Lab Sciences Limited</td><td>24.3</td></tr><tr><td>Acutaas Chemicals Limited</td><td>70.7</td></tr><tr><td>Supriya Lifeciencies Limited</td><td>29.7</td></tr></table> <p>Note: P/E ratio is calculated as on 21st August, 2025.</p>					Company Name	P/E ratio	Kronox Lab Sciences Limited	24.3	Acutaas Chemicals Limited	70.7	Supriya Lifeciencies Limited	29.7																						
Company Name	P/E ratio																																		
Kronox Lab Sciences Limited	24.3																																		
Acutaas Chemicals Limited	70.7																																		
Supriya Lifeciencies Limited	29.7																																		
Promoters	<ul style="list-style-type: none"><li>Punitkumar R. Rasadia</li><li>Meet Atulkumar Vachhani</li><li>Mamata Punitkumar Rasadia</li></ul>																																		
Objects of the issue	<ul style="list-style-type: none"><li>Funding capital expenditure requirements for Proposed Expansion.</li><li>Full or partial repayment and/or prepayment of certain outstanding secured borrowings (term loan) availed by the Company.</li><li>Funding the working capital requirements of the Company.</li><li>General corporate purposes.</li></ul>																																		
COMPILED & PREPARED BY SHAH INVESTOR’S HOME LTD   ALL RIGHTS RESERVED																																			

LOTS	SHARES	PRICE
Retail		
1	164	14,924
2	328	29,848
3	492	44,772
4	656	59,696
5	820	74,620
6	984	89,544
7	1,148	1,04,468
8	1,312	1,19,392
9	1,476	1,34,316
10	1,640	1,49,240
11	1,804	1,64,164
12	1,968	1,79,088
13	2,132	1,94,012
S-HNI		
14(Min)	2,296	2,08,936
67(Max)	10,988	9,99,908
B-HNI		
68(Min)	11,152	10,14,832

DISCLAIMER

The information provided by or in this newsletter is generally from the press reports, electronic media, research websites and other media. It also includes information from interviews conducted, analysis, views expressed by our research team. Investors shouldnot rely solely on the information contained in this publication and must make their own investment decision based on their specific objectives and financial positions and using such independent advisor as they believe necessary. The material and the information provided herein are not and should not be construed as an advice to buy or sell any of the securities named in this newsletter. SIHL may or may not hold positions in any of the securities named in this newsletter as a part of its business. Past performance is not necessarily an indication of future performance. SIHL does not assure for accuracy and correctness of information of reports in this newsletter.

